Clinical trials
Malignant Primary Gliomas clinical trials
Below are recruiting malignant primary gliomas clinical trials, each written for real people, not researchers. We’re tracking 36 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT05278208RecruitingPhase 1/Phase 2
Lutathera for high-grade brain tumors that returned or got worse
This trial tests if Lutathera, a radioactive drug that targets certain tumors, can help children and young adults with high-grade brain tumors or meningiomas that have come back or are growing. It aims to see if the treatment is safe and works.
Aurora, ColoradoAges 4–39 - NCT03684109Recruiting
MRI scans to study brain tumors using molecular imaging
This study uses special MRI scans to better “characterize” (study) gliomas, a type of brain tumor, using information from your brain tissue. You may be eligible if you’re an adult with a suspected or confirmed glioma and you already need a biopsy or surgery.
Miami, FloridaAges 18 years+ - NCT05553041RecruitingEarly Phase 1
PET-MRI scan test for aggressive brain tumors in children
This early-phase study uses a special PET scan plus MRI to help doctors tell apart tumor changes in children with aggressive gliomas. It may help find whether treatment is working or if the tumor is progressing, while also mapping tumor activity in the brain.
Philadelphia, PennsylvaniaAges 1–21 - NCT06630260RecruitingPhase 1/Phase 2
Avutometinib and Defactinib for brain tumors
This trial tests two oral drugs, avutometinib and defactinib, in people with aggressive brain tumors like glioblastoma. The goal is to see if this combination can shrink tumors or stop them from growing.
CambridgeAges 16 years+ - NCT07391215RecruitingPhase 1/Phase 2
Paxalisib for newly diagnosed glioblastoma after standard treatment
This trial tests a drug called paxalisib in people with a newly diagnosed aggressive brain tumor (glioblastoma) who have just finished standard radiation and chemotherapy. The goal is to see if adding paxalisib can help prevent the tumor from coming back by targeting a specific pathway in the cancer cells.
SuttonAges 16 years+ - NCT06585527RecruitingPhase 1
TS-2021 for recurrent malignant brain tumors
This trial tests the safety and effectiveness of a new drug called TS-2021 for people whose high-grade brain tumor has come back after initial treatment. It may be an option if you previously had surgery, radiation, or chemotherapy and are now facing a recurrence.
Beijing, Beijing MunicipalityAges 18–65 - NCT05555550RecruitingEarly Phase 1
PET-MRI scan to study low-grade brain tumors in children
This early-phase study tests how well a special PET-MRI scan (using a radioactive tracer) can find and measure low-grade brain tumors. It may help doctors better track these tumors while you start or continue treatment.
Philadelphia, PennsylvaniaAges 1–21 - NCT05622409Recruiting
Tissue and genetic data registry for diffuse glioma in adults
This study collects tumor tissue and basic medical information to better understand the genes involved in adult diffuse glioma. It may help future treatments by building a detailed research database and matching patients to study arms.
Kaohsiung CityAges 20 years+ - NCT04771520RecruitingPhase 2
Avapritinib for tumors with specific KIT or PDGFRA changes
This Phase 2 trial studies avapritinib, a targeted medicine, for people whose cancer has specific KIT or PDGFRA genetic changes. It may help shrink or slow growth of certain advanced cancers, including some brain tumors, when standard treatments have not worked or for specific glioblastoma cases.
Houston, TexasAges 18 years+ - NCT05099003RecruitingPhase 1/Phase 2
Selinexor plus radiation for newly diagnosed brain tumors
This trial studies whether adding selinexor to standard radiation can improve outcomes for children and young teens with certain newly diagnosed high-grade brain tumors (including DIPG). It’s designed for specific tumor types and genetic markers, and people must be able to start treatment soon after diagnosis.
Birmingham, AlabamaAges 1–21 - NCT06914479RecruitingPhase 1
Gene therapy and valacyclovir for recurrent brain tumors in young people
This trial tests a new gene therapy that uses two special viruses and an oral antiviral drug (valacyclovir) to treat brain tumors that have come back in children and young adults. The therapy is given right after surgery to remove the tumor, with the goal of helping your immune system fight the cancer.
Ann Arbor, MichiganAges 3–39 - NCT04732065RecruitingPhase 1
ONC206 for certain brain tumors in children and young adults
This Phase 1 study tests ONC206, a new targeted medicine, for diffuse midline gliomas (DMG) with a specific gene change (H3K27 altered) and for some other recurrent brain/spinal cord cancers. It is designed to find the right dose and see whether it can control or shrink tumors after initial treatment or when the cancer returns.
San Francisco, CaliforniaAges 2–21 - NCT06468176Recruiting
Remote program for memory and thinking after brain tumor
This study tests a remote program to help with memory and thinking problems caused by a grade 2 or 3 brain tumor. It is for people who have had surgery and are at least 6 months past any radiation or chemotherapy.
Montpellier, HéraultAges 18 years+ - NCT05030298RecruitingPhase 1
Pre-op focused radiation for aggressive brain tumor
This early-phase study tests a type of very targeted radiation given before surgery for people with a high-grade (aggressive) brain tumor. The goal is to see if this approach is safe and potentially improves treatment, while collecting tumor and blood samples for research.
Phoenix, ArizonaAges 18 years+ - NCT05293197RecruitingPhase 1
Safety study of repeated blood-brain barrier opening for pediatric brain tumors
This Phase 1 study tests whether a device can safely and repeatedly open the blood-brain barrier (a protective shield in the brain) in children with malignant brain tumors. It aims to help the tumor treatment work better while watching for safety issues.
ParisAges 5–17 - NCT01638130Recruiting
Study of support needs in high-grade brain tumor patients
This study asks people with a high-grade brain tumor and their caregivers about their experiences and support needs. It may help researchers understand what patients and families need during and after chemotherapy.
Leuven, Vlaams-BrabantAges 18 years+ - NCT07612917Recruiting
Brain Activity Changes in Glioma Patients During Treatment
This study tracks how brain activity and connections change in patients with gliomas (brain tumors) as they receive treatment. Researchers use special brain scans to understand how treatment affects the brain's function, which may help improve care for glioma patients in the future.
Linz, Upper AustriaAges 18–64 - NCT07126990Enrolling by invitationPhase 1/Phase 2
A new virus therapy for untreated high-grade glioma
This trial tests a modified virus that may help treat a type of brain cancer called high-grade glioma. It is for patients who have not yet had any treatment for their tumor.
Beijing, Chaoyang DistrictAges 18–80 - NCT06988475RecruitingPhase 2/Phase 3
Capmatinib for cancers with MET gene changes
This study tests an oral drug called capmatinib for people whose cancers have specific changes in the MET gene (except for one type of lung cancer). It aims to see if the drug can shrink tumors or slow their growth.
BelfastAges 18 years+ - NCT03896568RecruitingPhase 1
Trial of stem cell therapy for recurrent high-grade brain tumors
This Phase 1 study tests an advanced stem-cell treatment (hMSC-DNX2401) for recurrent high-grade glioma, including certain brain tumor types that come back. It aims to see if the treatment can be safely delivered and whether it can help control the tumor after standard therapies have already been tried.
Houston, TexasAges 18 years+ - NCT06160492RecruitingPhase 3
Testing a Glowing Dye to Improve Brain Tumor Removal
This trial compares two surgical techniques for removing malignant brain tumors: one using a special dye (5-ALA) that makes tumor cells glow under a blue light, versus the standard white light surgery. The goal is to see if the dye-guided approach helps surgeons remove more of the tumor safely.
Guangzhou, GuangdongAges 18–70 - NCT04945148RecruitingPhase 2
Metformin plus radiation and chemo for glioblastoma subtype
This Phase 2 study tests whether adding metformin to standard radiation and temozolomide (chemo) can improve outcomes for people with newly diagnosed glioblastoma of a specific metabolic subtype. It aims to see if this combination is safer and more effective than standard treatment alone.
Suresnes, Hauts de SeineAges 18 years+ - NCT05588141RecruitingPhase 1/Phase 2
Zotiraciclib for recurrent brain tumors with IDH mutations
This early-phase study tests zotiraciclib in people with recurring diffuse gliomas (brain tumors) that have an IDH1 or IDH2 mutation. It may help slow the tumor or shrink it by targeting a specific change in tumor biology.
Bethesda, MarylandAges 15 years+ - NCT06917885RecruitingPhase 1
CUE-102 for Recurrent Glioblastoma: A Safety Study
This study tests an experimental drug, CUE-102, for people with recurrent glioblastoma. It aims to see if the drug is safe and how well it works. You may be eligible if your tumor has come back once, you have a specific genetic marker (HLA-A*0201), and you are not on other treatments.
Boston, MassachusettsAges 18 years+
Hear when a new Malignant Primary Gliomas trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for malignant primary gliomas?
- Yes. Clin2 currently lists 36 recruiting malignant primary gliomas studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a malignant primary gliomas trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a malignant primary gliomas trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.